Noopur Raje, MD, Director of the Multiple Myeloma Program at Massachusetts General Hospital, discusses the safety and efficacy results of the CRB-402 trial, which evaluated bb21217 in patients with relapsed/refractory multiple myeloma. These findings were shared at the 2021 American Society of Hematology Annual Meeting.
Advertisement
Related Posts
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
A study finds shortened overall survival with thrombotic events more severe in arterial thrombosis than venous thrombosis.
This orally available, selective inhibitor of XPO1 is the first agent of its kind to receive commercialization approval.
BCMA–directed CAR Ts were a vital advancement to RRMM treatment. Now, oncologists wonder which agent works best.
The CARTITUDE-4, KarMMa-3, and DREAMM-7 trials are paving the way for immunotherapy in multiple myeloma.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.